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Abstract
Neogenin is a type I transmembrane glycoprotein with a large ectodomain containing tandem
immunoglobulin-like and fibronectin type III (FNIII) domains. Closely related to the tumor
suppressor gene DCC, neogenin functions in critical biological processes through binding to
various ligands, including netrin, repulsive guidance molecules, and the iron regulatory protein
hemojuvelin. We previously reported that neogenin binds to hemojuvelin through its membrane-
proximal fifth and sixth FNIII domains (FN5-6), with domain 6 (FN6) contributing the majority of
critical binding interactions. Here we present the crystal structure of FN5-6, the hemojuvelin-
binding fragment of human neogenin, at 1.8 Å. The two FNIII domains are orientated nearly
linearly, a domain arrangement most similar to that of a tandem FNIII-containing fragment within
the cytoplasmic tail of the β4 integrin. By mapping surface-exposed residues that differ between
neogenin FN5-6 and the comparable domains from DCC, which does not bind hemojuvelin, we
identified a potential hemojuvelin binding site on neogenin FN6. Neogenin FN5, which does not
bind hemojuvelin in isolation, exhibits a highly electropositive surface, which may be involved in
interactions with negatively-charged polysaccharides or phospholipids in the membrane bilayer.
The neogenin FN5-6 structure can be used to facilitate a molecular understanding of neogenin’s
interaction with hemojuvelin to regulate iron homeostasis and with hemojuvelin-related repulsive
guidance molecules to mediate axon guidance.
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1. Introduction
Neogenin is a type I transmembrane glycoprotein expressed in multiple tissues including
brain, kidney, liver, and skeletal muscle (Meyerhardt et al., 1997; Vielmetter et al., 1997).
Closely-related to the tumor suppressor molecule DCC (Deleted in Colorectal Cancer)
(Vielmetter et al., 1994), neogenin is composed of four immunoglobulin (Ig)-like domains
followed by six fibronectin type III (FNIII) domains, a transmembrane region, and a
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cytoplasmic domain (Vielmetter et al., 1994; Vielmetter et al., 1997). Neogenin functions in
a variety of developmental and metabolic processes (Wilson and Key, 2007), and several
ligands have been identified, including netrin, repulsive guidance molecules (RGMs)
(Matsunaga and Chedotal, 2004; Matsunaga et al., 2004; Rajagopalan et al., 2004), and the
iron regulatory protein hemojuvelin (Zhang et al., 2005).
While netrin-1 and neogenin mediate chemoattractive axon guidance, the neogenin/RGMa
interaction functions specifically in axon repulsion (Wilson and Key, 2006). Neogenin has
also been implicated as a dependence receptor (Bredesen et al., 2005), such that it triggers
apoptosis in the absence of a ligand RGM molecule, whereas the ligand-bound state inhibits
this effect (Matsunaga and Chedotal, 2004; Matsunaga et al., 2004). Downstream signaling
elicited by the binding of neogenin to RGMa involves the Rho family of small GTP-binding
proteins, which regulate cytoskeletal dynamics by controlling actin filaments and causing
growth cone collapse (Conrad et al., 2007). Pre-incubation of netrin-1 inhibits this signaling,
indicating either that netrin-1 occludes the RGMa-binding site on neogenin, or that a
different signaling cascade is initiated to counteract the Rho-mediated signaling (Conrad et
al., 2007).
In hepatocytes and perhaps also skeletal muscle, neogenin is involved in iron homeostasis
through interactions with hemojuvelin, also known as HFE2 or RGMc (Zhang et al., 2005).
Hemojuvelin is a glycosylphosphatidylinositol (GPI)-anchored protein that shares sequence
similarity with RGMa and RGMb, which, unlike hemojuvelin (RGMc), are expressed
predominantly in the nervous system (Schmidtmer and Engelkamp, 2004). Hemojuvelin is
an upstream modulator of hepcidin, a peptide hormone that regulates iron flux in mammals
(Lin et al., 2005). Interaction with neogenin has been suggested to initiate retrograde
trafficking of membrane-bound hemojuvelin to the Golgi and trans-Golgi network for
further processing before soluble hemojuvelin is released from the cell (Maxson et al., 2009;
Zhang et al., 2007; Zhang et al., 2008). The ratio of membrane-bound and soluble forms of
hemojuvelin is believed to be important for determining the amount of signal sent to the
nucleus through the bone morphogenetic protein (BMP)/hemojuvelin pathway, which
regulates hepcidin expression levels (Babitt et al., 2006).
We previously described biochemical studies using neogenin ectodomain deletion mutants
to localize the hemojuvelin-binding site to the two membrane-proximal FNIII domains
(FN5-6) (Yang et al., 2008). The FN5-6 fragment was as effective as the intact neogenin
ectodomain in competing with cell membrane neogenin both in vitro (Zhang et al., 2008)
and in vivo (Zhang et al., 2009), suggesting that the FN5-6 region contains the hemojuvelin-
binding region on neogenin. While FN5 did not bind detectably to hemojuvelin, FN6 alone
bound hemojuvelin, although more weakly than FN5-6, suggesting a potential contribution
from the domain linking region in the binding interaction (Yang et al., 2008).
Here we report the crystal structure of the hemojuvelin-binding fragment of human
neogenin, FN5-6, at 1.8 Å resolution. Each domain adopts the canonical FNIII fold, with the
two domains arranged nearly linearly, surprisingly similar to the arrangement of a pair of
tandem FNIII domains from the cytoplasmic tail of the β4 integrin. The neogenin FN5
domain displays a highly positively-charged surface, a feature shared with DCC FN5 and
other proteins known to bind heparan sulfate (Bennett et al., 1997; McLellan et al., 2006). In
addition to the possibility of interacting with negatively-charged carbohydrate or protein
ligands, we suggest that the positive surface on the neogenin FN5 domain may promote
interactions with negatively-charged phospholipids to facilitate exposure of the
hemojuvelin-binding FN6 domain to hemojuvelin proteins on the surface of another cell. To
gain insight into which portion of neogenin FN5-6 interacts with hemojuvelin, we mapped
non-conserved residues from the comparable domains of DCC, which does not bind
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hemojuvelin, onto the neogenin FN5-6 structure. One side of the FN6 domain, comprising
strands C, C’, F, and G, contains a high concentration of non-conserved surface residues,
suggesting that this face of the molecule contains the potential hemojuvelin-binding site.
2. Materials and Methods
2.1 Crystallization and data collections
Neogenin FN5-6, corresponding to the fifth and sixth FNIII domains of human neogenin
(residues 853-1054) plus a C-terminal 6x-His tag, was expressed in baculovirus-infected
insect cells and purified from supernatants as previously described (Yang et al., 2008). This
version of neogenin FN5-6 was previously referred to as sFNIII 5-6 to distinguish it from a
longer version of these domains (FNIII 5-6; residues 851-1103). The longer version bound
to hemojuvelin with ~18 fold higher affinity than FN5-6 (Yang et al., 2008), but did not
crystallize, presumably due to disorder of the C-terminal extension. The best crystals were
obtained from FN5-6 purified from culture media supplemented with 0.5 mg/L tunicamycin
(Sigma) to inhibit addition of N-linked glycans. Crystallization screening was done using a
Mosquito nanoliter handling system (TTP LabTech) with drops containing 200 nL protein
plus an equal volume of reservoir solution. Initial crystals grew in mother liquor containing
0.1 M Tris, pH 8.5, 0.2 M ammonium sulfate, 25% PEG-3350 at 20°. Larger crystals were
obtained in a Qiagen 24-well screw-top hanging drop plate using the same mother liquor. A
single crystal was cryo-preserved in mother liquor supplemented with 5% glycerol and a
native data set was collected on an R-AXIS-VI rotating anode X-ray generator (Rigaku) at
100 K.
2.2 Structure determination and model refinement
Data were processed by Denzo and scaled using Scalepack (Otwinowski and Minor, 1997)
in the orthorhombic space group C2221 (a = 52.6 Å, b = 112.9 Å, c = 80.9 Å). The
calculated Matthews coefficient (VM=2.5 Å3/Da) (Matthews, 1968) suggested a solvent
content of 51% and one molecule per asymmetric unit. The structure was solved by
molecular replacement using the program Phaser (McCoy et al., 2007) and search models
derived from NMR structures of individual domains of neogenin (PDB codes 1X5J and
1X5K) in which residues not present in our construct were deleted. Solvent-flattened
electron density maps for model building were generated using the program DM (CCP4,
1994). After rigid body refinement, the model was iteratively improved using cycles of
refinement using CNS (Brunger et al., 1998) and manual rebuilding using COOT (Emsley
and Cowtan, 2004) into 2Fo-Fc annealed omit maps. The final model (Rcryst= 20.0% and
Rfree = 23.4%) consists of neogenin residues 853-899 and 903-1052 (residues 900-902 were
disordered), and 293 water molecules (Table 1). For analyses of contacts and buried surface
areas, FN5 was defined as residues 853-949, and FN6 was defined as residues 952-1052.
The CCP4 program Areaimol (CCP4, 1994; Lee and Richards, 1971; Saff and Kuijlaars,
1997) was used to calculate buried surface area using a 1.4 Å probe and to identify
interacting residues using the following criteria: a distance of <3.5 Å and a hydrogen bond
angle of >90° for hydrogen bonds and a maximum distance of 4.0 Å for van der Waals
interactions. Figures were prepared by Pymol (DeLano, 2002).
3. Results
3.1 Overview of the neogenin FN5-6 structure
Initial crystallization trials with insect cell-expressed neogenin FN5-6 yielded crystals that
diffracted to only 15 Å. The expression of FN5-6 was repeated in the presence of
tunicamycin, an inhibitor of N-linked glycosylation. Neogenin FN5-6 derived from
tunicamycin-treated cells migrated as a slightly smaller apparent molecular weight than its
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untreated counterpart, consistent with successful inhibition of glycan attachment to the
single predicted N-linked glycosylation site in FN5-6 (data not shown), and crystals
obtained from the treated protein diffracted to 1.8 Å. A molecular replacement solution was
obtained by searching simultaneously for the two individual FNIII domains.
The structure of neogenin FN5-6 reveals two domains arranged in an extended conformation
(Figure 1A). The neogenin FNIII domains share the canonical FNIII folding topology, with
each FNIII domain containing two anti-parallel β-sheets, one formed by β-strands A, B, and
E and the other by β-strands C’, C, F, and G. Preceding strand G in both domains is a
polyproline II helix, a common feature of FNIII domains (Huber et al., 1994). Another
polyproline II helix (residue 1-5) is present in strand A in the FN5 domain and a short 310
helix is found between strands C and C’ in the FN6 domain. The two domains interact via a
hydrogen bonding network (Figure 1B) that stabilizes the extended conformation observed
for the structure in the crystals. The hydrogen bonding network, taken together with a lack
of obvious crystal contacts that would promote the observed interdomain conformation,
suggest that the domain arrangement in the crystals would be preserved in solution.
3.2 Comparison with other FNIII domain structures
The DaliLite server (Holm et al., 2008) was used to compare the neogenin FN5-6 structure
with other FNIII domains. In isolation, the closest structural homolog of neogenin FN5 is
the FN1 domain from the plectin-bound β4 integrin (de Pereda et al., 2009), and neogenin
FN6 is most closely related to DCC FN6 (PDB code 2EDE; to be published). We also
compared neogenin FN5-6 to available tandem FNIII structures including the β4 integrin
cytoplasmic domain (de Pereda et al., 1999), neuroglian FN1-2 (Huber et al., 1994), NCAM
FN1-2 (Carafoli et al., 2008), fibronectin FN7-10 (Leahy et al., 1996), NCAM2 FN1-2
(PDB code 2JLL; to be published), and Ihog FN1-2 (McLellan et al., 2006). The neogenin
FN5-6 domain arrangement was most similar to the arrangement of FNIII domains in the
intracellular region of the β4 integrin (Supplementary Figure 1A), both in the interdomain
tilt angle and the relative rotation angle (Table 2). A total of ~500 Å2 was buried between
the two neogenin FNIII domains, an intermediate value for buried surface areas in tandem
FNIII domain structures, which ranged from 280 Å for NCAM2 FN1-2 to 1170 Å for Ihog
FN1-2.
Electrostatic potential calculations revealed that neogenin FN5 is highly positively charged
(Figure 1C), a feature shared with only a few other FNIII domains with structures available
in the Protein Data Bank: of 80 available structures of FNIII domains, the only highly
positively-charged domains were from the FN5 domain of DCC (PDB code 2EDD; to be
published) (Figure 1C), FN1 from Ihog (McLellan et al., 2006), and FNIII domains from
four other unpublished structures (PDB codes 1X4Z, 1UEN, 1WFT, and 1UJT). Calculated
electrostatic potential surfaces for a subset of these FNIII structures (the available tandem
FNIII domain structures) are shown in Supplementary Figure 1B.
3.3 Sequence comparison with DCC molecule and implications for ligand binding
We previously showed that isolated neogenin FN6 (sFNIII 6; residues 952-1054) bound to
hemojuvelin with an affinity of ~2 μM, almost 1000-fold more weakly than neogenin
FN5-6, whereas isolated neogenin FN5 (sFNIII 5; residues 853-952) showed no detectable
binding to hemojuvelin (Yang et al., 2008). These results suggested that the hemojuvelin-
binding epitope (and by analogy, the RGM-binding epitope) on neogenin is primarily
located in FN6. To gain insight into potential hemojuvelin/RGM-binding interface(s) on
neogenin, we mapped residues from DCC onto the neogenin FN5-6 structure. Previous
studies demonstrated that hemojuvelin does not bind DCC, although neogenin FN5-6 and
DCC FN5-6 share 64% sequence identity and 83% similarity (Figure 2A) and DCC is the
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closest homolog of neogenin (Zhang et al., 2005). Thus a concentration of non-conserved
residues could represent a potential hemojuvelin/RGM binding interface on neogenin. A
portion of FN6 comprising the 310 helix in the C-C’ loop, the C’ strand, and the loop
between strands E and F is enriched in non-conserved surface residues, suggesting its
potential involvement in binding hemojuvelin (Figure 2B).
The highly positive nature of the neogenin FN5 domain (Figure 1C) suggests a model
(Figure 3) in which the FN5 domain interacts with negatively-charged phospholipids on the
membrane bilayer to expose the membrane-proximal FN6 domain of neogenin for trans
(between cells) interactions with RGMs (Yamashita et al., 2007). Alternatively, the basic
patch on FN5 could bind to an as yet unidentified highly negatively-charged protein ligand
or to negatively-charged polysaccharide chains, such as heparan sulfate, as has been
demonstrated for DCC FN5 (Bennett et al., 1997) and for Ihog (McLellan et al., 2006).
4. Discussion
Tandem FNIII domains are found in many signal-transducing cell surface receptors,
including gp130, Ihog, neuroglian, and neogenin. Although a FNIII fold can be identified
from sequence information alone, the arrangement of tandem FNIII domains cannot be
predicted from a sequence. Structures of tandem FNIII domains have revealed a variety of
domain arrangements, ranging from nearly linear (e.g., β4 integrin) to slightly or completely
bent (e.g., NCAM, neuroglian, fibronectin, and Ihog FNIII domains) (Supplementary Figure
1A). The crystal structure of the hemojuvelin-binding neogenin FN5-6 fragment reported
here reveals a nearly linear domain arrangement. Surprisingly, this arrangement is most
similar to the arrangement of intracellular FNIII domains in the cytoplasmic tail of the β4
integrin. The significance of the structural similarity between tandem FNIII domains in the
extracellular region of neogenin and the intracellular region of an integrin is unknown.
The neogenin FN5-6 structure revealed an unusually electropositive surface, which is shared
by only a few other FNIII domains, including DCC FN5 and Ihog FN1. Both DCC FN5 and
Ihog FN1 bind to heparan sulfate (Bennett et al., 1997; McLellan et al., 2006), suggesting
that neogenin FN5 may also interact with heparan or other negatively-charged
polysaccharide chains. Alternatively, or perhaps in addition to, binding to heparan sulfate,
the positive charges on neogenin FN5 could facilitate ligand (hemojuvelin or RGM) access
to the membrane-proximal FN6 domain through interactions between FN5 and negatively-
charged lipids on the membrane bilayer (Figure 3). The surface of DCC FN5 is also highly
positive (Figure 1C) and the basic residues in the DCC and neogenin FN5 domains are
mostly conserved (Figure 2A), suggesting a similar function for DCC FN5. Consistent with
this idea, the netrin-binding site on DCC has been mapped to a nearby region; either FN4 or
FN5 (Geisbrecht et al., 2003; Kruger et al., 2004).
The discovery of hemojuvelin as a co-receptor for BMP during activation of hepcidin
expression (Babitt et al., 2006) suggested the possibility of using BMP antagonists for the
treatment of anemia (Browne and Reddan, 2009). Alternatively, since the neogenin FN5-6
fragment described here has been shown to suppress BMP-mediated hepcidin expression
both in vitro and in vivo (Zhang et al., 2009), it may be possible to treat anemia by using this
fragment. Identification of a potential hemojuvelin-binding site on neogenin FN6 (Figure
2B) may be informative in designing such a drug if modifications are needed.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Crystal structure of neogenin FN5-6. (A) Ribbon diagram of the neogenin FN5-6 structure.
N- and C-termini are labeled. β-strands A, B, and E are blue, strands C, C’, F, and G are
purple, polyproline helices are orange and a 310 helix is green. A dashed line indicates the
disordered loop missing in the final model. (B) Hydrogen bonding (dotted yellow lines) at
the inter-domain interface. Oxygen atoms are red and nitrogen atoms are blue in the
highlighted side-chains. (C) Electrostatic potential surfaces for neogenin FN5-6 and DCC
FN5 (PDB code 2EDD). Electrostatic potentials were calculated using the APBS tool (Baker
et al., 2001) and plotted from −7 kT/e (red, electronegative) to +7 kT/e (blue,
electropositive).
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Figure 2.
Structure-based sequence alignment of the FN5-6 regions of human neogenin and DCC. (A)
Sequence alignment of neogenin FN5-6 with the counterpart region of DCC (GenBank
accession codes AAC51287 and NP_005206). Secondary structure elements determined
from the structure of neogenin FN5-6 are indicated above the sequences (arrows for β-
strands and springs for helices). Non-conserved residues representing potential interaction
sites with hemojuvelin are highlighted in red, residues that are similar but not identical are
highlighted in light brown, and conserved residues are not highlighted, with the exception of
conserved positively-charged residues in FN5, which are marked with an asterisk. (B)
Ribbon diagram and surface representation of neogenin FN5-6 using the color scheme from
panel A to highlight non-conserved regions (red) as potential binding sites for hemojuvelin.
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Figure 3.
Hypothetical model for how interactions between neogenin FN5 and negatively-charged
phospholipids on the surface of the neogenin-expressing cell could facilitate interactions
between hemojuvelin on the surface of another cell and the hemojuvelin-binding site on
neogenin FN6. The neogenin FN5-6 structure is shown as in Figure 1C as an electrostatic
surface, with the highly positive FN5 domain (blue) interacting with negatively-charged
lipids (red). The remaining domains of neogenin are represented as cyan (Ig-like domains)
and pink shapes (FNIII domains). A black arrow points to the 310 helix within the potential
hemojuvelin binding site in the FN6 domain.
Yang et al. Page 11
J Struct Biol. Author manuscript; available in PMC 2011 October 01.
H
H
M
I Author M
anuscript
H
H
M
I Author M
anuscript
H
H
M
I Author M
anuscript
H
H
M
I Author M
anuscript
H
H
M
I Author M
anuscript
H
H
M
I Author M
anuscript
Yang et al. Page 12
Table 1
Data collection and refinement statistics
Unit cell Space group C2221
Cell dimensions a, b, c (Å) 52.6, 112.9, 80.9
Data collection
Resolution (Å) 32.8-1.8 (1.86-1.80)
aRmerge (%) 5.9 (37.8)
Completeness 99.3 (98.2)
I/σI 28.2 (4.2)
Mean redundancy 3.8 (3.7)
No. of unique/total reflections 22544/85823
Refinement statistics
Resolution (Å) 32.8-1.8
No. reflections used 22481
No. reflections in working/test set 21391/1090
Rcryst/ Rfree (%) 20.0/23.4
No. Atoms (B factor: Å2)
Protein 1577 (23.75)
Water 293 (35.49)
RMS deviations
Bond length (Å) 0.010
Angle (°) 1.596
Ramachandran plot (%)
Preferred 187 (96.4%)
Allowed 7 (3.6%)
Outlier 0 (0.0%)
a
Rmerge (%) = 100 × ∑∣I−<I>∣/∑I, where I is the integrated intensity of a given reflection. Numbers in parentheses are statistics for the highest
resolution shell.
b
Rcryst (%) = 100 × ∑ ∣Fobs−Fcalc∣/∑Fobs, where the Fobs and Fcalc are the observed and calculated structure factor amplitudes for all
reflections in the working set.
b
Rfree was calculated as described for Rcryst but summed over the 5% of reflections that were not included in the refinement.
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Table 2
Interdomain tilt, rotation angles and buried surface area
PDB code Tilt (°)* Rotation (°) Buried surface area(Å2) ***
neogenin FN5-6 TBD 169 148 501
neuroglian FN1-2 1CFB 104 172 308
fibronectin FN7-8 1FNF 129 112 601
fibronectin FN8-9 1FNF 134 158 540
fibronectin FN9-10 1FNF 157 42 338
β4 integrin 1QG3 155;156** 150;153 392
NCAM FN1-2 2VKW 57;59 140;140 530
NCAM2 FN1-2 2JLL 122 89 280
Ihog FN1-2 2IBB 42 137 1170
*
Tilt angle (defined as the angle between the long axes of two adjacent domains) was calculated using the program Dom_angle (Su et al., 1998).
Rotation angle (kappa in polar coordinates) was calculated using COOT by superimposing the secondary structures of the two domains.
**
Two angles were calculated due to slight conformational differences between two copies of the same molecule.
***
Total buried surface areas were calculated using CCP4 program AREAIMOL and a 1.4 Å probe.
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